Between August 1993 and February 1994, 25 patients with follicular or transformed follicular lymphoma had bone marrow harvested at St Bartholomew's Hospital (SBH) with a view to proceeding to high-dose treatment comprising: cyclophosphamide 60 mg/kg × 2 and total body irradiation, 200 cGy × 6, supported by autologous bone marrow transplantation (ABMT). The marrow mononuclear cell fraction was treated in vitro with four anti-B cell antibodies and baby rabbit complement. The aim of this study was to determine whether in vitro treatment of the marrow could remove morphologically undetectable lymphoma cells. PCR analysis for the t(14;18) was used to determine the presence or absence of lymphoma. At the time of the bone marrow harvest, 21/25 bone marrow samples were positive for the t(14;18), in 15/22 patients, the rearrangement could also be demonstrated in peripheral blood. After in vitro treatment, 18/21 samples (86%) remained 'PCR positive'. Sequence analysis of the t(14;18) PCR products was performed on the latter and on lymph node biopsy material taken at diagnosis from 12 patients. The same t(14;18) sequences were found in the bone marrow harvest samples as in the patients' original biopsies. These results suggest that this form of in vitro treatment does not completely eradicate the t(14;18) bearing clone. New and better methods need to be developed. Keywords: PCR analysis; t(14;18); ABMT; follicular lymphoma
serious risk, in a disease in which marrow infiltration is common. 10, 11 Various in vitro techniques have therefore been developed to remove such cells from autologous marrow. 12, 13 Since 1985, the use of high-dose treatment with ABMT has been evaluated in younger patients with follicular lymphoma at St Bartholomew's Hospital (SBH). 15 The marrow mononuclear cell fraction was treated with the monoclonal antibody anti-CD20 and baby rabbit complement. 9 The efficacy of the in vitro procedure was monitored at the molecular level by the polymerase chain reaction (PCR), able to detect the t(14;18) translocation at a level of 1/10 5 . In the majority of cases, 'PCR negativity' was not achieved and when it occurred, it was not clinically relevant. 14 In contrast, at the Dana Faber Cancer Institute, Boston, three anti-B cell antibodies and complement were reported to render the marrow 'PCR negative' in half the cases. 15 Furthermore, such 'PCR-negativity' was shown to be the single most important prognostic factor for freedom from recurrence. 15 The current study was therefore conducted to determine whether in vitro treatment similar to that used in Boston could eliminate t(14;18) bearing cells in patients with follicular lymphoma receiving CY + TBI at SBH.
Patients and methods

Patients
Twenty-five patients from whom bone marrow was harvested with a view to proceeding to CY + TBI + ABMT are the subject of this analysis. All had recurrent follicular or transformed follicular lymphoma. Their clinical characteristics are shown in Table 1 . Prior to the bone marrow harvest, remission status was evaluated by computed tomography of the chest, abdomen and pelvis, together with bilateral bone marrow aspirates and trephine biopsies. Treatment only proceeded if the patient was deemed to be in complete remission (CR), or almost CR (defined as tumour masses less than 2 cm in diameter at no more than three sites and/or bone marrow infiltration of less than 20% of the intra-trabecular space.
Bone marrow harvest and in vitro treatment
At least 1 l of bone marrow was harvested under general anaesthesia, the cells washed three times on an IBM 2991 
Treatment
Patients received 60 mg/kg of cyclophosphamide on 2 consecutive days with mesna, followed by total body irradiation 200 cGy, twice daily for 3 days. 9 The thawed bone marrow was reinfused within 24 h of the last dose of radiotherapy.
The harvested cells were incubated for 30 min with an excess of saturating concentrations of the four MoAbs at room temperature. After incubation, cells coated with the MoAbs were depleted using complement lysis. Complement was added at a concentration predetermined for each lot. The cells were incubated with complement at 37°C for 30 min. After lysis, the cells were pelleted by centrifugation, washed three times and the whole procedure repeated twice.
Patients' samples
Lymph node or bone marrow samples from the time of presentation were available for 15/25 patients. DNA was prepared by phenol-chloroform extraction, following detergent lysis and proteinase K digestion. The samples taken at the time of bone marrow harvest comprised aliquots of at least 2 × 10 6 mononuclear cells, before and after three cycles of in vitro treatment. The cells were incubated at 37°C for 30 min in medium containing deoxyribonuclease (Sigma, St Louis, MO, USA) at a final concentration of 2.5 mg/ml. This prevented cell clumping and ensured that DNA from the lysed cells was not copurified during DNA extraction. 20 
PCR analysis
A two-step PCR analysis was used for the detection of the t(14;18). The risk of contamination was minimised as far as possible by preparation of stocks of reaction mixtures in advance, use of a separate part of the laboratory for the PCR analysis, use of negative controls for each reaction and disposable equipment. The analysis on diagnostic samples for different patients was completed before their remission samples were analysed.
The DOHH 2 cell line bearing the t(14;18), (derived from the immunoblastic transformation of a follicular lymphoma) was used as a positive control. The sensitivity of the reaction was established using serial dilutions of the DOHH 2 cell line with lymphocytes from the peripheral blood of healthy volunteers at a ratio of up to one t(14;18) positive cell to 10 6 normal cells. For each sample, at least three separate amplifications were performed. 0.5 g of genomic DNA was amplified in a total volume of 50 l of PCR reaction mixture consisting of 50 mm KCl, 10 mm Tris-HCl Ph 9, 2.5 mm MgCl 2 , 0.01% (w/v) gelatin, 1% (v/v) Triton X-100, 1 m of each primer and 0.2 mm dNTPs (dATP, dCTP, dGTP, dTTP). One unit of Taq polymerase (Promega) was added to each tube after an initial 10 min denaturation period. Forty cycles were performed with a denaturation at 95°C for 45 s, annealing at 58°C for 45 s and extension at 72°C for 1 min. A sample was scored as positive if at least one of the three reactions was positive.
Nine combinations of primers were used at the first step, including two different primers for the mbr and one for the mcr as shown in Table 2 , in combination with primers for the IgH region including the J H consensus primer complementary to a sequence common to each J H exon, as well as two specific for the J6 and J4 regions to ensure that all potential breakpoints within the 2.5 kb region bounded by JH6 and JH1 were Ͻ1.5 kb distant from a J H amplification primer.
Following the initial step, for all samples, a nested PCR reaction was performed, in a new reaction mixture using nested primers for the mbr and mcr, in combination with the J H consensus primer for the reactions where the J6 or J4 primers were used at the first step, or an inner J H consen- GAT GGC TTT GCT GAG AGG TAT J H inner consensus:
CAG GGT TCC TTG GCC CCAG Sequencing primer:
CAC AGA CCC ACC AGA GCC C sus primer for the reactions where the J H consensus primer was used at the first step. Thirty cycles were performed using the same cycling conditions as previously. The sequence of all primers used is shown in Table 2 . Following completion of the reactions, 7.5 l of the final PCR product were subjected to electrophoresis in a 2% agarose gel and visualised by ethidium bromide staining and ultraviolet illumination.
For sequencing of the PCR products, the J H inner consensus or the J H consensus primers were used in biotinylated form, to allow immobilisation of the amplification products on the surface of streptavidin-coated microbeads (Dynabeads M-280, streptavidin; Dynal, Oslo, Norway). After successful amplification was determined by electrophoresis, the remaining PCR product was passed through a Sephadex G-50 column (Pharmacia P-L Biochemicals, Uppsala, Sweden) to remove unincorporated primers. Sequencing was performed using the PRISM Ready Reaction Dye Deoxy Termination cycle sequencing Kit protocol (Perkin-Elmer Applied Biosystems, Warrington, UK). The samples were analysed on an automated ABI sequencer. The bcl-2-specific primer used for sequencing was complementary to nucleotide sequences internal to the sequence of the inner mbr primer and is also shown in Table 2 .
Results
Clinical outcome
Twenty-four of the 25 patients whose marrow was treated in vitro have proceeded to myeloablative therapy. Twentytwo of 24 are alive with a median follow-up of 10 months (range 1-21 months).
One treatment-related death was associated with the development of radiation induced pulmonary fibrosis at 5 months. One patient developed recurrent lymphoma with transformation to high-grade histology and died of refractory disease 10 months after the high-dose treatment.
All patients engrafted successfully with a median time to platelet recovery (Ͼ20 × 10 9 /l) of 32 days (range 17-83) and to neutrophils (Ͼ0.5 × 10 9 /l) of 36 days (range 20-54). Only one patient had not engrafted 6 weeks after reinfusion of treated marrow and an untreated 'backup' marrow was used successfully.
PCR analysis
Diagnostic material: In 15/25 patients, lymph node or bone marrow samples were available from the time of initial diagnosis. In all, the breakpoint occurred at the mbr. The PCR products were sequenced to determine the specific N insertion and the J H region involved in the translocation. This was considered necessary to confirm that the clone detected in subsequent samples was the same as the original and not a de novo clone, and to exclude any possibility of cross-contamination between different patients' samples. Table 3 , 21/25 of the bone marrow samples were positive for the t(14;18) at the time of the harvest. Diagnostic material was available in two of the four cases in whom the t(14;18) could not be demonstrated, both were positive for the t(14;18). Minimal morphological involvement of the bone marrow at the time of the harvest was present in two of the 25 cases; both were found to be positive by PCR analysis (Table 1) . Two patients with transformed follicular NHL had 'PCR positive' bone marrow, and in 1/2 with impending transformation, the t(14;18) was also detected.
BM at time of harvest: As shown in
Peripheral blood at time of harvest:
Blood samples were checked in 22/25 cases. The presence of the t(14;18) was demonstrated in 15/22 (68%) ( Table 3 ). This percentage is lower than that for bone marrow analysed concurrently (84%). In all cases positive in the peripheral blood, the bone marrow was also found to be positive.
BM after in vitro treatment:
Eighteen of 21 positive samples (86%) remained PCR positive after treatment with four monoclonal antibodies and complement. Thus, in only three patients was the t(14;18) PCR detectable clone eradicated. These patients had no evidence of transformation or bone marrow involvement prior to the harvest. All were treated in second partial remission.
Concurrent PCR positivity of the peripheral blood and bone marrow at the time of harvest is not predictive of the efficiency of purging as shown in Table 4 although statistical analysis cannot be performed.
Sequence analysis of the t(14;18) breakpoints was performed in the 21 samples that were PCR positive before the in vitro treatment and in the 18 that remained positive after in vitro treatment. Sequencing was also performed on the 15 PCR positive peripheral blood samples and on the 12 diagnostic samples available. All 21 cases had mbr breakpoints. The N insertion specific for each patient and the J H segment involved in the translocation are shown in Table  4 . The location of the breakpoints is shown in relation to the first base of the 5Ј end of the inner mbr primer.
Discussion
These results confirm that, as expected, the majority of patients (21/25) had PCR detectable t(14;18) cells in their bone marrow and/or peripheral blood at the time of the bone marrow harvest. This is in accordance with previous observations in patients with follicular lymphoma that cells bearing the t(14;18) can be detected at the time of clinical remission, in patients with both localised and advanced disease. [21] [22] [23] Bone marrow was more likely to show PCR positivity for the t(14;18) than the peripheral blood. These findings confirm data from the Dana Faber Cancer Institute (DCFI), where it has been shown that bone marrow is more informative than peripheral blood in detecting minimal residual disease at the time of and after ABMT. 24 In a previous analysis of 50 patients receiving high-dose treatment and ABMT at SBH, it was shown that in the majority of cases, in vitro treatment with one MoAb and complement was not able to render the bone marrow free of PCR detectable t(14;18) bearing cells.
14 These results differ from those reported from the DFCI, where in 50% of cases, using three monoclonal antibodies (anti-CD20, anti-CD22, anti-CD10) and complement the marrow became PCR negative. 15 The current study therefore addressed the question of whether the use of four MoAbs at SBH could improve the efficacy of the in vitro treatment in a similar group of patients. The results for the first 25 patients suggest that in the majority of cases (84%), the t(14;18) bearing clone cannot be eradicated with a level of sensitivity of 1 lymphoma cell in 10 5 normal cells. Thus, the theoretical assumption that the reduced ability to remove lymphoma cells at SBH as compared to the DFCI was associated with the use of one instead of three MoAbs is not supported by these findings. However, the question of sensitivity of the PCR assay may be crucial. Bone marrow samples from 11 of the patients described in this report were subsequently re-tested using a different, less sensitive methodology. 25 Samples from two patients who were found to be 'PCR positive' before and after the in vitro treatment were found to be negative using the less sensitive assay. It is also possible that such a difference in sensitivity also accounts for the discrepancy between the results reported in this study and those reported from Boston. The possibility that persistent positivity could be a reflection of contamination by DNA from dead cells during purging should be discounted because of the use of DNAase prior to DNA extraction in these experiments. 20 The difficulty in removing clonogenic t(14;18) bearing cells is subject to different interpretations. It is possible that the antigenic profile of the clonogenic tumour cell is not covered by the panel of four MoAbs being used. An alternative explanation is that modulation of the surface antigen after attachment of the monoclonal antibody to its ligand could impede complement-mediated lysis. It is also possible that lymphoma cells are resistant to such lysis. In favour of the latter interpretation are results from the DFCI, where it has been shown that immunomagnetic bead depletion is superior to complement-mediated lysis, since it resulted in PCR negativity in all cases, whereas for the same patient samples, complement lysis rendered only 44% of the samples free of lymphoma cells at the molecular level. 20 These results have also been confirmed by another study where PCR negativity was achieved using a cocktail of five MoAbs and immunomagnetic beads in 3/4 cases of follicular lymphoma. 26 The problems of complementmediated lysis can further be aggravated by the presence of an anticomplementary factor associated with human bone marrow. 27 An alternative explanation might also be that the target antigens are expressed at such low density that lysis is not affected. 28 The important question to be answered actually relates to the significance of reinfusing PCR positive bone marrow during high-dose treatment. The short follow-up period in the current study does not allow any conclusion to be drawn. Although the prognostic significance of the t(14;18) has been the subject of controversy, several investigators have shown that the reinfusion of PCR positive bone marrow is associated with significantly shorter remission duration 14, 15, 29, 30 and the presence of the t(14;18) at follow-up (but probably not early after transplantation) is associated with a significantly higher risk of relapse. 31, 32 It is not yet clear, however, whether recurrence derives from the reinfused cells, or is due to endogenous triggering of lymphomagenesis, and hence the inability to 'purge' simply reflects resistance of these lymphoma cells to treatment, probably associated with weak expression of the targeted antigens.
However, recent studies in solid tumours and in other haematological malignancies using gene marking techniques have demonstrated that residual tumour cells in reinfused marrow can at least contribute to recurrence following high-dose treatment. 33, 34 Better techniques are clearly needed to deplete the haematopoietic stem cell population of tumour cells. The possibility of lymphoma cell depletion of the autograft by using CD34 positive selection followed by negative depletion or, as recently shown, by ex vivo expansion are alternatives [35] [36] [37] that need confirmation.
